In a remarkable collaboration, Viralgen partners with Elaaj Bio to expedite gene therapy solutions for CDKL5 Deficiency Disorder, targeting critical needs in rare pediatric care.

In a pivotal collaboration, Viralgen and Elaaj Bio align their expertise to drive the development of innovative gene therapy targeting CDKL5 deficiency disorder, aiming for clinical advancement.

Viralgen and Elaaj Bio announce a partnership aimed at developing a gene therapy for the rare pediatric condition known as CDKL5 deficiency. Their work is crucial for accelerating clinical development.

5 apuntes sanitarios para terminar la semana. 1️⃣ El lunes publicamos un informe sobre financiación de medicamentos innovadores en España. Es la primera vez que el Ministerio de Sanidad hace públicos...

EpilepsyGTx and Viralgen are collaborating on a gene therapy program aimed at treating refractory epilepsy with promising human trials approaching.

EpilepsyGTx partners with Viralgen to enhance the manufacturing of EPY201, a groundbreaking gene therapy for refractory epilepsy, ahead of critical trials.

Viralgen and Axovia are collaborating to manufacture an investigational gene therapy targeting retinal dystrophy in Bardet-Biedl Syndrome patients.

El director ejecutivo de la 'biotech' donostiarra augura un gran futuro a Euskadi como polo de referencia, pero aún con retos por resolver

Bij Viralgen, een producent van gentherapie voor biotech- en farmabedrijven in het Baskische San Sebastian, heeft met Jimmy Vanhove een Vlaming de leiding. ‘Mijn abonnement bij de lokale voetbalclub w...

EpilepsyGTx and Viralgen collaborate on gene therapy using AAV vectors to advance treatment for refractory epilepsy, affecting millions worldwide.

EpilepsyGTx and Viralgen are collaborating to advance a specialized AAV gene therapy aimed at epilepsy, promising innovative treatment options for patients worldwide.

EpilepsyGTx partners with Viralgen to push their AAV gene therapy, EPY201, aimed at treating refractory epilepsy, into human trials, supporting millions.

Danobatgroup eta Zunibalen berrikuntza, Amporen zigilu industriala eta Bayerrek bultzatutako Viralgen nazioarteko proiekzioa ere saritu zituen Euskal Enpresaren Gauak

Bij Viralgen, een producent van gentherapie voor biotech- en farmabedrijven in het Baskische San Sebastian, heeft met Jimmy Vanhove een Vlaming de leiding. ‘Mijn abonnement bij de lokale voetbalclub was de beste integratie’, zegt hij.

Damià Tormo és una d’eixes espècies rares de científic que arrisca i triomfa en el salt a l'empresa. El que s’anomena un científic emprenedor. Va canviar la ciència de base per la gestió d'empreses d'investigació en biotecnologia. Firmes com Viralgen, que va vendre per 4.000 milions a la multinacional Bayerns. Una trajectòria que acaba de coronar el Premi Jaume I a la Revelació Empresarial i què ha repassat en Les notícies del matí.

Viralgen collaborates with Elaaj Bio to push forward a pioneering gene therapy program for CDKL5 Deficiency Disorder, aiming for clinical development.

Viralgen collaborates with Elaaj Bio to enhance a gene therapy program for CDKL5 deficiency disorder, a rare neurological condition affecting children.

Apertura Gene Therapy and Viralgen have partnered to manufacture TfR1 CapX, a breakthrough capsid for gene therapies aimed at central nervous system diseases.